Granite Point Capital Management L.P. boosted its stake in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 415.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,550 shares of the biotechnology company’s stock after acquiring an additional 185,000 shares during the period. Granite Point Capital Management L.P.’s holdings in BioTime were worth $494,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Voya Investment Management LLC boosted its holdings in shares of BioTime by 38.3% in the 2nd quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 8,996 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of BioTime by 95.6% in the 3rd quarter. Jane Street Group LLC now owns 44,548 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 21,778 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of BioTime by 402.4% in the 4th quarter. SG Americas Securities LLC now owns 62,301 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 49,900 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of BioTime in the 2nd quarter valued at $142,000. Finally, Nationwide Fund Advisors boosted its holdings in shares of BioTime by 61.2% in the 2nd quarter. Nationwide Fund Advisors now owns 71,857 shares of the biotechnology company’s stock valued at $226,000 after purchasing an additional 27,279 shares in the last quarter.

Shares of BioTime, Inc. (NYSEAMERICAN:BTX) opened at $2.60 on Wednesday. BioTime, Inc. has a twelve month low of $2.10 and a twelve month high of $3.62. The firm has a market capitalization of $327.31, a price-to-earnings ratio of 6.05 and a beta of 1.95.

BTX has been the topic of a number of research analyst reports. BidaskClub downgraded BioTime from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 18th. Zacks Investment Research downgraded BioTime from a “hold” rating to a “sell” rating in a report on Friday, October 20th. Finally, Lake Street Capital initiated coverage on BioTime in a report on Friday, February 2nd. They issued a “buy” rating and a $8.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. BioTime presently has an average rating of “Hold” and an average target price of $5.81.

COPYRIGHT VIOLATION NOTICE: “Granite Point Capital Management L.P. Buys 185,000 Shares of BioTime, Inc. (BTX)” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2018/02/14/granite-point-capital-management-l-p-buys-185000-shares-of-biotime-inc-btx.html.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.